Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. (PubMed, Lancet Respir Med) - Oct 4, 2025 - P2 | "The acceptable safety profile and efficacy analyses of taladegib support further investigation in a phase 2b trial in patients with IPF (WHISTLE-PF)."
Journal • P2a data • Alopecia • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pain • Pulmonary Disease • Respiratory Diseases
|
|
A B Yu-Lin; A DiFrancesco; A Ramírez-Rivera; B P Hobbs; F Thien; I Buendia-Roldan; J G Goldin; J Hood; J Pitman; J W Song; M de Los Rios; P C Perea; T M Maher
|